Vyant Bio (OTCMKTS:VYNT) Shares Up 7.8%

Vyant Bio, Inc. (OTCMKTS:VYNT)’s share price shot up 7.8% during mid-day trading on Thursday . The company traded as high as $0.20 and last traded at $0.19. 19,100 shares were traded during mid-day trading, a decline of 88% from the average session volume of 161,822 shares. The stock had previously closed at $0.18.

Vyant Bio Stock Performance

The stock’s 50-day moving average price is $0.19 and its 200-day moving average price is $0.18. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.86 and a quick ratio of 2.86.

Institutional Trading of Vyant Bio

A hedge fund recently raised its stake in Vyant Bio stock. Captrust Financial Advisors increased its position in Vyant Bio, Inc. (OTCMKTS:VYNT) by 405,350.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 202,725 shares of the company’s stock after acquiring an additional 202,675 shares during the period. Captrust Financial Advisors owned approximately 3.45% of Vyant Bio worth $113,000 at the end of the most recent reporting period.

About Vyant Bio

Vyant Bio, Inc, a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD).